Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II tacrolimus in diffuse large B- or T-cell lymphoma with activated calcineurin/NFAT pathway
2009-017269-49Phase 2Active
- Sponsor
- Institut Curie
- Start
- Jan 2010
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tacrolimus in diffuse large B-cell lymphoma (DLBCL) and T-cell lymphoma, sponsored by Institut Curie. Primary endpoints: Tumor response at 3 months and Toxicity. Started Jan 2010; status: active.
02
Drugs
tacrolimus
03
Conditions
diffuse large B-cell lymphoma (DLBCL)T-cell lymphoma
Beyond the preview
Go deeper on 2009-017269-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017269-49.